title: Surgical coronary revascularization and antiarrhythmic therapy in survivors of out-of-hospital cardiac arrest.
abstract: BACKGROUND
  Patients who survive out-of-hospital cardiac arrest are at high risk for recurrent arrest. Coronary artery bypass grafting (CABG) confers a survival advantage, but it is unclear whether antiarrhythmic drugs or an implanted defibrillator confer added benefit. This study was designed to determine predictors for further treatment, survival, and therapeutic internal cardiac defibrillator (ICD) discharge in this patient population.
  
  
  METHODS
  One hundred and eight patients undergoing CABG after out-of-hospital cardiac arrest were identified over a 12-year period. Case records were retrospectively reviewed. Follow-up was obtained and predictors of outcome events were analyzed.
  
  
  RESULTS
  Fifty-four (50%) patients underwent CABG only. Fifty-four received additional treatment that included ICD placement in 23 (21%), antiarrhythmic medications in 19 (18%), or both in 12 (11%). Predictors of ICD placement included left ventricular ejection fraction (LVEF) less than 40% and perioperative intraaortic balloon counterpulsation. ICD or medical management increased survival in patients with LVEF <40%. Predictors of increased mortality included age >65 years, Cleveland Severity Score >8, and female gender. Predictors of therapeutic ICD discharge included age >65 years, reoperative CABG, LVEF <40%, and positive postoperative electrophysiological (EP) study. No patient with a negative postoperative EP study received an ICD, and none suffered sudden cardiac death during follow-up.
  
  
  CONCLUSIONS
  Patients with coronary artery disease anatomically suitable for CABG who survive an acute out-of-hospital cardiac arrest should undergo EP testing after CABG. Approximately half of these patients are adequately treated by CABG alone. The remainder may benefit from ICD placement or medical antiarrhythmic management.
authors.affiliation: Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
authors.forename: Abeel A
authors.initials: AA
authors.lastname: Mangi
authors.forename: Theodore J
authors.initials: TJ
authors.lastname: Boeve
authors.forename: Gus J
authors.initials: GJ
authors.lastname: Vlahakes
authors.forename: Cary W
authors.initials: CW
authors.lastname: Akins
authors.forename: Alan D
authors.initials: AD
authors.lastname: Hilgenberg
authors.forename: Jeremy N
authors.initials: JN
authors.lastname: Ruskin
authors.forename: Brian M
authors.initials: BM
authors.lastname: McGovern
authors.forename: David F
authors.initials: DF
authors.lastname: Torchiana
mesh_terms: D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000401:mortality / Q000601:surgery*; D017147:Defibrillators, Implantable; D004632:Emergency Medical Services; D005260:Female; D006323:Heart Arrest / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007423:Intra-Aortic Balloon Pumping; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000601:surgery*; D010043:Outcome and Process Assessment, Health Care; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000889:Anti-Arrhythmia Agents